摘要:
This invention relates to the active ingredient of a pharmaceutical composition consisting of micronized monoclinic symmetry crystals (MMSCs) of sodium {[4-({[4-bromo-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl] acetyl }amino)-3-chlorophenyl] - sulfonyl}(propanoyl)azanide with an average particle diameter ≤130 µm and methods of use thereof in the treatment of Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS).
摘要:
A fluorinated imide salt compound of the present invention is a compound represented by General Formula (1). In General Formula (1), m represents 1 or 2, n represents an integer from 1 to 4, α represents 1 or 2, and X α+ represents an α-valent metal ion, a primary ammonium ion, a secondary ammonium ion, a tertiary ammonium ion, a quaternary ammonium ion, or NH 4 + .
摘要:
Benzoyl urea derivatives that are alpha helical peptide mimetics that mimic BH3-only proteins, compositions containing them, their conjugation to cell-targeting moieties, and their use in the regulation of cell death are disclosed. The benzoyl urea derivatives are capable of binding to and neutralising pro-survival Bcl-2 proteins. Use of the benzoyl urea derivatives in the treatment and/or prophylaxis of diseases or conditions associated with deregulation of cell death are also disclosed.
摘要:
The invention relates to a method for producing compounds of formula (Ia), in particular to a method for producing N -[4-(cyclopropylcarbamoyl)phenylsulfonyl]-2-methoxybenzamide.
摘要:
The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.